Trials / Completed
CompletedNCT04888949
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Rohto Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
Detailed description
Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mesenchymal stem cell | 1\*10\^8 cells are administered once a week, total four times intravenously. |
| BIOLOGICAL | Placebo | Commercially available saline. |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2023-05-18
- Completion
- 2023-05-18
- First posted
- 2021-05-17
- Last updated
- 2023-11-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04888949. Inclusion in this directory is not an endorsement.